Clinical trials: Motor Vehicle Accident
Ebola Virus Disease
Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
The aim of this study is to investigate the persistence of the vaccine induced immune response between 24 - 60 months following primary vaccination.
- Trial name
- PRISM (NCT03140774)
- Testing
- Previously exposed to Ebola vaccine
- Where
- 2 sites in United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola, Ebola Zaire
A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
The purpose of this study is to assess two new Ebola vaccines: cAd3-EBO Z at 3 different doses, and a second vaccine, MVA-BN® Filo, at 3 different doses.
- Trial name
- NCT02240875
- Testing
- cAd3-EBO Z at 1 x 10^10 vp, cAd3-EBO Z at 2.5 x 10^10 vp, cAd3-EBO Z at 5 x 10^10 vp
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Hemorrhagic Fever, Ebola
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and…
- Trial name
- NCT02598388
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 7 sites in United States, Kenya and 4 more
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Atopic Dermatitis
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.
- Trial name
- NCT00316602
- Testing
- IMVAMUNE
- Where
- 22 sites in United States, Mexico
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Malaria, Vivax
VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines
This is an open label, Phase IIa, controlled human malaria infection (CHMI) study aimed to assess whether the new vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP can protect against malaria infection.
- Trial name
- NCT04009096
- Testing
- ChAd63 PvDBP and MVA PvDBP
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
18-42 Year Old Healthy Vaccinia-naïve Subjects
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
To demonstrate the efficacy of MVA-BN® in terms of vaccinia-specific Plaque Reduction Neutralization Test (PRNT) antibody response and by showing that vaccination prior to administration of ACAM2000® results in an attenuated take.
- Trial name
- NCT01913353
- Testing
- MVA BN®, ACAM2000®
- Where
- South Korea
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Influenza
A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine
This is a single blinded placebo controlled phase I study, to assess the safety and immunogenicity of co-administration of the candidate influenza vaccine MVA-NP+M1 with seasonal influenza vaccine.
- Trial name
- NCT01465035
- Testing
- TIV and MVA-NP+M1
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19 Vaccines
Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate
This will be a phase I, single-center trial, including a total of 30 participants in two cohorts. Cohort 1 (n=6): Healthy male or female adults aged 18 - ≤ 60 previously primary immunized with two vaccinations with any regimen…
- Trial name
- NCT05226390
- Testing
- MVA-SARS-2-ST
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Hannover Medical School
Malaria
A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration
The purpose of this study is to assess the safety and immunogenicity of novel routes of administration of the candidate malaria vaccines ChAd63 encoding ME-TRAP and MVA encoding ME-TRAP.
- Trial name
- NCT03084289
- Testing
- ChAd63-METRAP, MVA ME-TRAP
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Concussion, Brain, Motor Vehicle Accident
Research Evaluating Sports ConcUssion Events - Rapid Assessment of Concussion and Evidence for Return
RESCUE-RACER is jointly sponsored by the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. The RESCUE-RACER programme evaluates motorsports competitors at baseline (CArBON) and post-injury (CARS).
- Trial name
- RESCUE-RACER (NCT03844282)
- Testing
- Clinical assessment (SCAT5), ImPACT, CANTAB
- Where
- United Kingdom
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
Musculoskeletal Pain
Vitamin D to ENhance TraUma REcovery
The main objective of this study is to determine whether the administration of a single dose of Vitamin D in the Emergency Department following a motor vehicle collision can improve musculoskeletal pain severity as well as reduce…
- Trial name
- VENTURE (NCT05458024)
- Testing
- Vitamin D 2
- Where
- 4 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Plasmodium Falciparum Malaria
CS DNA MVA Trial in Mampong, Ghana
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of 2 doses of a malaria vaccine (DNA) followed by a dose of another type of malaria vaccine (MVA) given as a "booster." Forty-eight adults in…
- Trial name
- NCT00377494
- Testing
- MVA-CSO Vaccine, PfCSP DNA (VCL-2510) Vaccine
- Where
- 2 sites in United States, Ghana
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
A Study of AdCh63 ME-TRAP Alone and With MVA ME-TRAP
This is an open label phase I study, to assess the safety of a novel malaria vaccine, AdCh63 ME-TRAP, simian adenovirus encoding Plasmodium falciparum antigens.
- Trial name
- NCT00890019
- Testing
- AdCh63 ME-TRAP, AdCh63 ME-TRAP; MVA ME-TRAP
- Where
- 2 sites in United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Respiratory Syncytial Virus Infections
MVA-BN-RSV Vaccine Trial
Phase 3 randomized, double blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults >=60 years of age
- Trial name
- NCT05238025
- Testing
- MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
- Where
- 120 sites in United States, Germany
- Volunteers
- 20,419 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Mpox (Monkeypox), Vaccination
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic…
- Conditions
- Mpox (Monkeypox), Vaccination, Immunogenicity, Safety
- Trial name
- PregInPoxVac (NCT06844487)
- Testing
- MVA-BN standard regimen, MVA-BN half-dose regimen
- Where
- Democratic Republic of the Congo
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Motor Vehicle Crash Injuries
Teenage Passenger Influences on Driving Performance of Teenage Drivers
This study, conducted at the University of Massachusetts at Amherst, will examine how male teenage driving performance varies in the presence or absence of male teenage passengers.
- Trial name
- NCT00716378
- Testing
- Teen Passenger Presence
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Healthy
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen…
- Trial name
- NCT02543567
- Testing
- Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp)
- Where
- 6 sites in United States
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus Disease, Hemorrhagic Fever
Phase 1 Trial of Ebola Vaccine in Mali
Ebola virus causes an infection known as Ebola virus disease (EVD). This is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02267109
- Testing
- Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z
- Where
- Mali
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Malaria
Efficacy of Candidate Malaria Vaccines in Senegalese Adults
Malaria transmission is falling in some parts of Africa as bed nets and anti-malarials become more widely available. However, transmission still persists and it appears that additional control measures are required.
- Trial name
- NCT01658696
- Testing
- ChAd63 ME-TRAP and MVA ME-TRAP, Rabies vaccine
- Where
- Senegal
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Monkeypox (Mpox)
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Randomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in…
- Trial name
- NCT07199569
- Testing
- Jynneos, MVA-BN (Quail)
- Where
- 10 sites in United States
- Volunteers
- 970 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic